Bannerbild German Brest Group

September 2021: iDFS and safety results of the randomized phase III GAIN-2 trial


We are delighted to inform you that our results on the GAIN-2 trial has been published in European Journal of Cancer

The GAIN-2 trial was designed to identify a superior intense dose-dense strategy for high-risk patients with early breast cancer. Here, we report an interim analysis, at which the predefined futility boundary was crossed.


  • Adjuvant dose-dense regimens and survival in high-risk breast cancer
  • Tailored dose-dense compared to intense dose-dense chemotherapy in high-risk breast cancer
  • Tailored dose-dense chemotherapy is superior in HR+/HER2-, lobular cancer and ≤50 years of age
  • High-grade toxicity was significantly higher with intense dose-dense regimen
  •  GAIN-2 results support the EBCTCG metaanalysis of increasing the dose intensity

Conclusion: iDFS is equal in both regimens, but tailoring dose-dense chemotherapy improved outcomes in HR+/HER2-, lobular cancer and patients ≤50 years.

Möbus V, Lück HJ, Ladda E, et al. Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2). Eur J Cancer. 2021;156:138-148.


GBG Forschungs GmbH
Dornhofstr. 10 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd